The Center for Biosimilars recaps the top 5 articles for the week of December 4.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 4.
Number 5: The efficient use of modeling and simulation may allow for better decision making that can increase the likelihood of successful outcomes in biosimilar development.
Number 4: At the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia, a research team will present findings that community-based lymphoma care is associated with guideline-discordant use of rituximab.
Number 3: Rival insulin makers Novo Nordisk and Sanofi both announced positive data on their products that could help them to stave off biosimilar and follow-on competition.
Number 2: Research shows that savings generated from the use of biosimilar filgrastim can expand access to high-cost drugs.
Number 1: A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold, so that treatments are more affordable and equally available to all Americans.
Finally, last week, our e-newsletter asked whether you think prescribers, patients, or payers are the key drivers of biosimilar uptake. To see results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.